| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
(+)-Schisandrin B targets reactive oxygen species (ROS) and oxidative stress pathways. It modulates Nrf2 and MAPK signaling pathways, and exerts anti-HIV-1 activity in H9 cells. The compound acts as an apoptosis inhibitor, nephroprotective agent, hepatoprotective agent, and antilipemic agent. Its neuroprotective effects are mediated through multiple mechanisms including antioxidant and anti-inflammatory actions.
|
|---|---|
| ln Vitro |
In vitro, (+)-Schisandrin B demonstrates inhibitory activity against HIV-1 in H9 cells with an EC50 of 0.8 mg/L. It exhibits antioxidant activity by reducing reactive oxygen species levels and shows anti-inflammatory effects in various cellular models. The compound also protects cells against oxidative stress-induced damage.
|
| ln Vivo |
In vivo, (+)-Schisandrin B provides hepatoprotective effects by protecting against liver injury. It supports cognitive function and may counteract age-related oxidative stress. The compound demonstrates cardioprotective effects in rodent models and exhibits anti-asthmatic activity. These effects are attributed to its antioxidant and anti-inflammatory properties.
|
| Enzyme Assay |
Cell-free assays for (+)-Schisandrin B include antioxidant activity measurements using DPPH or ABTS radical scavenging assays. The compound's ability to reduce ROS is quantified using fluorometric probes in cell-free systems. Its anti-inflammatory activity can be assessed by measuring the inhibition of pro-inflammatory enzyme activities such as COX or LOX using spectrophotometric or chromatographic methods.
|
| Cell Assay |
In vitro cellular assays typically involve treating various cell lines (e.g., H9 cells for anti-HIV activity, hepatocytes for hepatoprotective studies) with (+)-Schisandrin B at concentrations ranging from 0.1 to 100 µM. Cell viability, ROS levels, and inflammatory cytokine production are measured using MTT assays, fluorescent probes, and ELISA, respectively. HIV-1 inhibitory activity is determined by measuring viral replication inhibition.
|
| Animal Protocol |
In vivo studies are conducted in rodent models of liver injury, cognitive impairment, or cardiac stress. (+)-Schisandrin B is administered orally or intraperitoneally at doses typically ranging from 10 to 200 mg/kg. Biochemical parameters in serum and tissue homogenates are analyzed, and histopathological examinations are performed to assess tissue protection.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (+)-Schisandrin B include good oral bioavailability due to its lipophilic nature. It is metabolized in the liver and can cross the blood-brain barrier. The compound undergoes extensive phase I and phase II metabolism, with metabolites excreted via bile and urine. Half-life and tissue distribution vary depending on the route of administration and dosage.
|
| Toxicity/Toxicokinetics |
Available toxicological data indicate that (+)-Schisandrin B has a favorable safety profile at therapeutic doses. No significant acute toxicity has been reported in animal studies. Chronic toxicity studies would be necessary for clinical development. The compound is generally recognized as safe based on its long history of use in traditional Chinese medicine.
|
| References | |
| Additional Infomation |
(+)-Schisandrin B is an organic heterotetracyclic compound found in Schisandra chinensis and Schisandra chinensis. It possesses nephroprotective, apoptosis-inhibiting, plant metabolism-enhancing, anti-asthmatic, antioxidant, anti-inflammatory, neuroprotective, hepatoprotective, and lipid-lowering effects. It is an organic heterotetracyclic compound belonging to the aromatic ether, oxoheterocyclic, and cyclic acetal groups. Schisandrin N has been reported to exist in Schisandra chinensis, closely related Schisandra chinensis, and other organisms with relevant data. See also: Schisandrin B (note moved to).
(+)-Schisandrin B is primarily a research compound with no FDA-approved indications. It is widely used in traditional Chinese medicine for liver protection and overall health. Its mechanisms involve antioxidant, anti-inflammatory, and mitochondrial function enhancement. Clinical trials for various indications including liver diseases and cognitive disorders are potentially warranted based on preclinical evidence. |
| Molecular Formula |
C23H28O6
|
|---|---|
| Molecular Weight |
400.46
|
| Exact Mass |
400.188
|
| CAS # |
82467-52-5
|
| PubChem CID |
158103
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
545.0±50.0 °C at 760 mmHg
|
| Flash Point |
220.4±30.0 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.543
|
| LogP |
6.46
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
29
|
| Complexity |
544
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C[C@H]1CC2=CC3=C(C(=C2C4=C(C(=C(C=C4C[C@H]1C)OC)OC)OC)OC)OCO3
|
| InChi Key |
RTZKSTLPRTWFEV-OLZOCXBDSA-N
|
| InChi Code |
InChI=1S/C23H28O6/c1-12-7-14-9-16(24-3)20(25-4)22(26-5)18(14)19-15(8-13(12)2)10-17-21(23(19)27-6)29-11-28-17/h9-10,12-13H,7-8,11H2,1-6H3/t12-,13+/m1/s1
|
| Chemical Name |
(9R,10S)-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4971 mL | 12.4856 mL | 24.9713 mL | |
| 5 mM | 0.4994 mL | 2.4971 mL | 4.9943 mL | |
| 10 mM | 0.2497 mL | 1.2486 mL | 2.4971 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
